Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is an uncommon clinicopathological entity first described in 1997, 1 although the actual incidence may be significantly underestimated because of the potential for confusion with plasmablastic lymphoma or poorly differentiated carcinoma. 2 The optimal therapy for advanced disease is not known for this aggressive subset of DLBCL. In this study we describe the challenges in the diagnosis and treatment of a patient we recently treated for ALK-positive DLBCL. Front-line autologous hematopoietic SCT with chemosensitive disease was inadequate for disease control, highlighting the very aggressive nature and poor prognosis of this subset of DLBCL.
Our patient, a 60-year-old man, presented with a mass at the base of his tongue in 2005. The tongue mass was excised and showed a plasma cell neoplasm composed predominantly of mature plasma cells (Figure 1a ), although mitotic figures were frequent (circle) and some areas showed plasmablastic differentiation. Evaluation for a systemic plasma cell disorder was negative. The patient was diagnosed with extramedullary plasmacytoma and received radiation with 50 Gy to the tongue base over a 5-week period in 25 fractions and 30 Gy to lymphatics in 15 fractions.
One year later, he developed severe low back pain and leg weakness. Evaluation including magnetic resonance imaging (MRI) of the lumbar spine revealed numerous spine metastases including L5 without cauda equina compression. Biopsy of L5 demonstrated a poorly differentiated malignancy with cytologic features suggestive of metastatic adenocarcinoma. The neoplastic cells were positive for CD138, a marker that can be expressed in both carcinoma and plasma cell neoplasms. There was no history of carcinoma or clinical findings to suggest a primary site. Because of his history of plasmacytoma as well as retroperitoneal lymphadenopathy visible on his lumbar spine MRI, we performed positive emission tomography (PET), which showed multiple hypermetabolic lymph nodes above and below the diaphragm, intense activity in the spleen and several additional bony hypermetabolic foci. A hypermetabolic right axillary lymph node was excised. The lymph node demonstrated infiltration by large, immunoblast-like cells with round nuclei and a single, central nucleolus (Figure 1c) . The atypical cells stained positive for CD45, CD138, ALK, epithelial membrane Ag and MUM1 (multiple myeloma oncogene 1). FISH with a break-apart probe to 2p23 showed separation of the ALK locus. With this new information, we stained his previous tongue lesion for ALK, which was diffusely positive (Figure 1b) . Lactate dehydrogenase (LDH) at this time was 383 U/L.
Given the worsening neurological symptoms, he received corticosteroids and underwent urgent radiation of 36 Gy in 12 fractions to L5, followed by combination CHOP chemotherapy. After six cycles of chemotherapy, only a few hypermetabolic foci remained in his spleen. He completed two more cycles of CHOP chemotherapy and then proceeded with autologous hematopoietic SCT as front-line therapy for chemosensitive disease. His initial (diagnosis) marrow was negative for lymphomatous involvement, as was his pretransplant marrow. He successfully mobilized 4.21 Â 10 6 CD34 þ cells/kg after G-CSF priming. After conditioning with BEAM, he was infused with his collected stem cells and engrafted without serious complications. His day-15 post transplant lymphocyte count failed to reach 500 cells/mL, a negative prognostic factor. 3 Fewer than 100 days after his transplant, he developed fevers, bone pain, hepatosplenomegaly and pancytopenia. PET scan demonstrated dramatic hypermetabolic activity in his marrow as well as in spleen and liver (Figure 2) . His LDH had risen to 5100 U/L. BM biopsy now demonstrated near-replacement by ALK-positive DLBCL, now with complex structural and numeric cytogenetic abnormalities in all 20 metaphases examined. The abnormalities included structural rearrangements of both chromosomes 2: the first translocated an intact ALK gene region onto chromosome 15q; the second represented an apparently balanced t(2;17)(p23;q23). Metaphase FISH verified ALK gene disruption associated with this 2;17 translocation. The t(2;17)(p23;q23) has been previously defined in DLBCL and may indicate involvement of the CLTC (clathrin heavy chain) gene. 4 We attempted salvage with high-dose corticosteroids to bridge him to other novel therapies; however, he did not respond. He deteriorated rapidly, and LDH rose further to 15 200 U/L. The patient elected at this point to receive comfort measures only and died 6 days after relapse diagnosis.
Our experience with this patient is congruous with previous reports of this lymphoma subtype carrying a dismal prognosis in the advanced stage setting. Therapeutic options for aggressive lymphomas, including front-line autologous transplant, 5 may be inadequate for long-term disease control and survival with ALK-positive DLBCL. 
